- Home
- MGRX vs BIVI Comparison
MGRX vs BIVI Comparison
Compare MGRX & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- BIVI
- Stock Information
- Founded
- MGRX 2021
- BIVI 2013
- Country
- MGRX United States
- BIVI United States
- Employees
- MGRX N/A
- BIVI N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- MGRX Technology
- BIVI Health Care
- Exchange
- MGRX Nasdaq
- BIVI Nasdaq
- Market Cap
- MGRX 18.6M
- BIVI 15.0M
- IPO Year
- MGRX 2023
- BIVI N/A
- Fundamental
- Price
- MGRX $1.71
- BIVI $6.03
- Analyst Decision
- MGRX
- BIVI
- Analyst Count
- MGRX 0
- BIVI 0
- Target Price
- MGRX N/A
- BIVI N/A
- AVG Volume (30 Days)
- MGRX 145.9K
- BIVI 66.5K
- Earning Date
- MGRX 08-13-2025
- BIVI 09-29-2025
- Dividend Yield
- MGRX N/A
- BIVI N/A
- EPS Growth
- MGRX N/A
- BIVI N/A
- EPS
- MGRX N/A
- BIVI N/A
- Revenue
- MGRX $511,084.00
- BIVI N/A
- Revenue This Year
- MGRX N/A
- BIVI N/A
- Revenue Next Year
- MGRX N/A
- BIVI N/A
- P/E Ratio
- MGRX N/A
- BIVI N/A
- Revenue Growth
- MGRX N/A
- BIVI N/A
- 52 Week Low
- MGRX $1.32
- BIVI $5.74
- 52 Week High
- MGRX $7.66
- BIVI $75.00
- Technical
- Relative Strength Index (RSI)
- MGRX 51.65
- BIVI 34.02
- Support Level
- MGRX $1.61
- BIVI $7.24
- Resistance Level
- MGRX $1.77
- BIVI $7.75
- Average True Range (ATR)
- MGRX 0.14
- BIVI 0.72
- MACD
- MGRX 0.02
- BIVI -0.10
- Stochastic Oscillator
- MGRX 43.68
- BIVI 8.78
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.